Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial



Mosenzon, Ofri, Wiviott, Stephen D, Cahn, Avivit, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Heerspink, Hiddo JL, Zelniker, Thomas A, Dwyer, Jamie P
et al (show 11 more authors) (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. LANCET DIABETES & ENDOCRINOLOGY, 7 (8). 606 - 617.

[img] Text
DECLARE main renal oucomes 6.5.19- Lancet D and E .docx - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (564kB)
Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 08 Oct 2019 09:17
Last Modified: 09 Sep 2022 22:13
DOI: 10.1016/S2213-8587(19)30180-9
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3057336